Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2017
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural MesotheliomaNamrata S Patil, Luisella Righi, Hartmut Koeppen, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
Tumori|April 1, 2022
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysisFabio Turco, Marcello Tucci, Tiziana Angusti, et al.
Future Oncology (London, England)|March 20, 2019
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancerOrazio Caffo, Gaetano Facchini, Elisa Biasco, et al.
Cancers|January 28, 2026
Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 StudyOrazio Caffo, Umberto Basso, Antonello Veccia, et al.
Prostate Cancer and Prostatic Diseases|January 25, 2026
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysisIsabella Saporita, Mariangela Calabrese, Federica Maria Carfi, et al.
Clinical Genitourinary Cancer|July 12, 2024
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future PerspectivesFabio Turco, Consuelo Buttigliero, Marco Donatello Delcuratolo, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
Clinical Genitourinary Cancer|December 11, 2024
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or EnzalutamideOrazio Caffo, Umberto Basso, Carlo Cattrini, et al.
Future Oncology (London, England)|April 28, 2025
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPCAntonello Veccia, Umberto Basso, Carlo Cattrini, et al.
Pageof 9